InsidersTradesSigma
Fulcrum Therapeutics, Inc. Stock: price and insider trades · United States · SEC (Form 4)
Track the Fulcrum Therapeutics, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Fulcrum Therapeutics, Inc. has logged 42 insider filings. Market capitalisation: €243.2m. The latest transaction was filed on 20 July 2026 (Acquisition). Among the most active insiders: Gould Robert J. The full history is accessible without an account.
42
Insider Decl.
n/a
Thresholds
€31m
16 ops.
Buy Volume
€17m
12 ops.
Sell Volume
48Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 20 July 2026
Declarations42 total
116,671 shares@ US$3.560.17% mcap27.9% of flowCommon StockSEC:0001178579-26-000016:0
Canonical exit: 14 Oct 2026 (T+90)
50,945 shares@ US$3.520.074% mcap12.1% of flowCommon StockSEC:0001178579-26-000016:1
Canonical exit: 15 Oct 2026 (T+90)
75,952 shares@ US$3.580.11% mcap30.6% of flowCommon StockSEC:0001178579-26-000014:2
Canonical exit: 12 Oct 2026 (T+90)
12,966 shares@ US$3.540.019% mcap5.2% of flowCommon StockSEC:0001178579-26-000014:0
Canonical exit: 11 Oct 2026 (T+90)
53,651 shares@ US$3.560.080% mcap21.5% of flowCommon StockSEC:0001178579-26-000014:1
Canonical exit: 12 Oct 2026 (T+90)
107,377 shares@ US$3.560.16% mcap42.8% of flowCommon StockSEC:0001178579-26-000014:3
Canonical exit: 13 Oct 2026 (T+90)
18,000 sharesCommon StockSEC:0001193125-26-290622:0
15,000 shares@ US$10.87260.031% mcap7.8% of flowCommon StockSEC:0001193125-26-037606:0
15,000 shares@ US$10.72380.030% mcap7.6% of flowCommon StockSEC:0001193125-26-037573:0
15,000 shares@ US$11.87260.034% mcap8.5% of flowCommon StockSEC:0001193125-26-004572:0
3,452 shares@ US$12.9282.2% of flowCommon StockSEC:0001193125-25-322740:0
1,377,020 shares@ US$13.3335.5% of flowCommon StockSEC:0001231919-25-000596:0
15,000 shares@ US$11.0339.0% of flowCommon StockSEC:0001193125-25-291392:0
498 shares@ US$5.064.0% of flowCommon StockSEC:0000950170-25-068038:0
8,500,000 sharesCommon StockSEC:0001415889-24-022127:0
150,000 shares@ US$3.2750.0% of flowCommon StockSEC:0000950170-24-081949:0
236 shares@ US$7.763.0% of flowCommon StockSEC:0000950170-24-056947:0
4,884 shares@ US$11.715591.9% of flowCommon StockSEC:0000950170-24-028827:0
43,360 shares@ US$11.347550.0% of flowCommon StockSEC:0000950170-24-025933:0
Canonical exit: 2 Jun 2024 (T+90)
210 shares@ US$3.311.1% of flowCommon StockSEC:0000950170-23-021245:0
1,923,076 shares@ US$13.0080.4% of flowCommon StockSEC:0001104659-23-006213:0
Canonical exit: 20 Apr 2023 (T+90)
6,766 shares@ US$15.005.0% of flowCommon StockSEC:0000899243-23-001803:0
122,334 shares@ US$7.02762.8% of flowCommon StockSEC:0001104659-23-001881:0
Canonical exit: 4 Apr 2023 (T+90)
4,089 shares@ US$5.99410.1% of flowCommon StockSEC:0001104659-22-130982:0
Canonical exit: 27 Mar 2023 (T+90)
98,787 shares@ US$5.89971.9% of flowCommon StockSEC:0001104659-22-129121:0
Canonical exit: 19 Mar 2023 (T+90)
25 of 42 declarations
Acerca de Fulcrum Therapeutics, Inc.
Geográficamente, la huella operativa de Fulcrum se concentra en el clúster biotecnológico de Boston/Cambridge, donde mantiene su sede y espacio de laboratorio. Esa ubicación proporciona acceso a talento, redes académicas y el ecosistema más amplio de ciencias de la vida de EE. UU., pero la empresa sigue siendo principalmente una organización de investigación y desarrollo con infraestructura comercial limitada. Los aspectos más destacados recientes incluyen actualizaciones positivas del estudio de fase 1b PIONEER de pociredir en SCD, planes para avanzar hacia un posible ensayo de registro en la segunda mitad de 2026, y una posición de caja más sólida a finales de 2025 tras una oferta pública de acciones. En general, Fulcrum sigue siendo una biotecnológica de enfermedades raras de alto riesgo y alto potencial, que cotiza en el NASDAQ Global Market en los Estados Unidos.
